APG Asset Management N.V. Purchases 6,258 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

APG Asset Management N.V. increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 11.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 61,017 shares of the medical research company’s stock after purchasing an additional 6,258 shares during the quarter. APG Asset Management N.V. owned approximately 0.12% of Charles River Laboratories International worth $11,761,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Tortoise Investment Management LLC boosted its stake in shares of Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after buying an additional 57 shares during the last quarter. Headlands Technologies LLC bought a new position in Charles River Laboratories International in the 1st quarter valued at $41,000. Brown Brothers Harriman & Co. increased its position in shares of Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 95 shares during the last quarter. Whittier Trust Co. of Nevada Inc. increased its position in shares of Charles River Laboratories International by 219.3% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 193 shares during the last quarter. Finally, Concord Wealth Partners raised its stake in shares of Charles River Laboratories International by 362.5% during the 1st quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock worth $70,000 after purchasing an additional 203 shares during the period. 98.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Argus restated a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. JPMorgan Chase & Co. cut shares of Charles River Laboratories International from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $270.00 to $205.00 in a report on Thursday, August 8th. TD Cowen reduced their price objective on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a report on Monday, August 12th. The Goldman Sachs Group lowered their target price on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. Finally, Barclays cut their price target on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and an average price target of $227.55.

Charles River Laboratories International Stock Up 0.0 %

CRL stock opened at $198.31 on Friday. The stock has a 50-day simple moving average of $207.15 and a two-hundred day simple moving average of $221.47. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The firm has a market capitalization of $10.21 billion, a PE ratio of 23.33, a PEG ratio of 4.09 and a beta of 1.36. The company has a quick ratio of 1.21, a current ratio of 1.58 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.03 billion. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has authorized a share repurchase program on Wednesday, August 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).